QWM
CYTK icon

Quaker Wealth Management’s Cytokinetics CYTK Stock Holding History

Quaker Wealth Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$682 Hold
8
– – ﹤0.01% 670
2026
Q1 		$528 Hold
8
– – ﹤0.01% 686
2025
Q4 		$509 Hold
8
– – ﹤0.01% 691
2025
Q3 		$440 Hold
8
– – ﹤0.01% 630
2025
Q2 		$265 Buy
+8
New +$278 ﹤0.01% 756

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quaker Wealth Management's CYTK Position: Q2 2026 in Review

Quaker Wealth Management held its Cytokinetics (CYTK) position steady in Q2 2026 at 8 shares worth $682. The position accounts for ﹤0.01% of the portfolio, ranked #670.

Quaker Wealth Management first reported a position in CYTK in Q2 2025 and has held it in 5 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Quaker Wealth Management held 8 shares of Cytokinetics worth $682 as of Q2 2026.
  • Quaker Wealth Management left its Cytokinetics share count unchanged in Q2 2026.
  • Cytokinetics made up ﹤0.01% of Quaker Wealth Management's portfolio in Q2 2026, its #670 holding.
  • Quaker Wealth Management first reported a position in Cytokinetics in Q2 2025 and has held it in 5 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Quaker Wealth Management's 13F filing for Q2 2026, filed 24 Jul 2026.